8-K: Cognition Therapeutics Launches New $75M ATM Offering

Cognition Therapeutics, Inc. has entered into a new 'at-the-market' equity offering agreement for up to $75 million, simultaneously terminating its previous $40 million program.

Summary

• Cognition Therapeutics, Inc. (CGTX) entered into a new Open Market Sale AgreementSM with Jefferies LLC on December 18, 2025.
• This agreement allows the company to sell, at its option, up to an aggregate of $75,000,000 of its common stock through an 'at-the-market' (ATM) offering.
• Jefferies LLC will serve as the sales agent or principal, receiving a commission of 3.0% of the gross sales price per share.
• The company simultaneously terminated its previous Controlled Equity OfferingSM Sales Agreement, which was established on December 23, 2022, with Cantor Fitzgerald & Co. and B. Riley Securities, Inc.
• Prior to its termination, the previous ATM program had approximately $12,500,000 remaining available for sale out of a total of $40,000,000.
• No termination penalties were incurred by the company for ending the previous agreement.

Sentiment

Score: 6

Explanation: The establishment of a larger capital raising facility is generally positive for financial flexibility, but the potential for dilution and the lack of assurance on share issuance introduce some uncertainty. It's a standard financing move for a biotech company.

Positives

• Secures a new, larger capital raising facility of up to $75,000,000, providing enhanced financial flexibility for future operations and research.
• The previous ATM program was terminated without incurring any termination penalties, avoiding additional costs.
• The new facility is established with Jefferies LLC, a prominent investment bank, which can facilitate efficient capital access.

Negatives

• The 'at-the-market' nature of the offering means potential dilution for existing shareholders as shares are sold over time.
• The company cannot provide assurances that it will issue any shares, indicating uncertainty regarding the actual amount and timing of capital to be raised.
• A 3.0% commission on gross sales will reduce the net proceeds received by the company from any shares sold.

Risks

• Potential dilution of existing shareholders if the company sells a significant number of shares under the new ATM offering.
• Uncertainty regarding the timing and amount of capital that will actually be raised, as the company cannot assure the issuance of shares.
• Market conditions could impact the price at which shares are sold, potentially leading to lower proceeds than anticipated.

Future Outlook

The company has established a new facility to potentially raise up to $75 million, providing future capital access, though there is no assurance that any shares will be issued.

Management Comments

• The Company cannot provide any assurances that it will issue any Shares pursuant to the Sales Agreement.

Industry Context

This ATM offering provides a flexible and cost-effective method for a biotechnology company like Cognition Therapeutics to access capital as needed, common for firms in research and development stages requiring ongoing funding for clinical trials and operations.

Comparison to Industry Standards

• ATM offerings are a standard capital-raising tool for small to mid-cap biotech companies, similar to those utilized by peers such as ACADIA Pharmaceuticals Inc. or Sage Therapeutics, Inc., to fund ongoing R&D without the immediate pricing pressure of a traditional underwritten offering.
• The 3.0% commission rate is within the typical range for ATM facilities, which often vary between 2% and 5% depending on the agent and market conditions, comparable to recent agreements seen with companies like Xencor, Inc. or Blueprint Medicines Corporation.

Stakeholder Impact

• Shareholders: Potential for dilution if shares are sold under the ATM offering, but also provides capital for company operations and growth.
• Creditors: Enhanced financial flexibility from potential capital raise could improve the company's ability to meet obligations.

Next Steps

• The company may, at its option, sell shares of common stock through Jefferies LLC under the new ATM offering.
• Jefferies LLC will use commercially reasonable efforts to sell shares based on the company's instructions.

Key Dates

Recommendation

The new ATM offering provides Cognition Therapeutics with increased financial flexibility to fund its operations and research, which is a positive. However, the potential for shareholder dilution and the inherent uncertainty of 'at-the-market' sales, coupled with the 3.0% commission, suggest a neutral stance. This is a standard financing mechanism for a development-stage biotech, not a significant catalyst for immediate upside or downside, warranting a 'hold' as investors await further operational updates or clinical trial results.

Keywords

Cognition Therapeutics, CGTX, ATM Offering, At-the-Market, Equity Offering, Capital Raise, Jefferies LLC, SEC Filing, Form 8-K, Common Stock, Dilution